<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139576</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1973-5495</org_study_id>
    <nct_id>NCT05139576</nct_id>
  </id_info>
  <brief_title>Practices of Vitamin D Supplementation Leading to Vitamin D Toxicity</brief_title>
  <official_title>Practices of Vitamin D Supplementation Leading to Vitamin D Toxicity: Experience From a Tertiary Care Center of a Low Middle Income Country</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University Hospital, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University Hospital, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the frequency toxicity (&gt;150 ng/ml) in subjects for 25-hydroxyvitamin D (25OHD)&#xD;
      and evaluate the vitamin D (VD) supplements used by these subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective cross-sectional study was conducted at the Section of Chemical Pathology,&#xD;
      Department of Pathology and Laboratory Medicine, AKUH Karachi Pakistan after approval from&#xD;
      Aga Khan University Hospital's Ethics Review Committee (ERC ID: 2019-1973-6924). Data of&#xD;
      subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those&#xD;
      with 25OHD levels &gt;150 ng/ml were contacted via telephone. Only the initial results of the&#xD;
      subjects tested at Clinical Laboratory were included. Those with incomplete clinical history,&#xD;
      25OHD levels &lt;150ng/ml, whose contact numbers were unavailable or not answering telephone&#xD;
      calls were excluded. To maintain confidentiality all identifiers were removed, and study&#xD;
      identity numbers were generated.&#xD;
&#xD;
      After explaining the reason for phone call, verbal informed consent was taken and clinical&#xD;
      information of calcium and VD supplementation including prescribed or self-medicated,&#xD;
      indications for prescription, formulation strength, total dosage, frequency, duration, and&#xD;
      calcium status was collected on a structured clinical history forms. The hypercalcemia was&#xD;
      labeled when serum calcium was &gt;10.2 mg/dl.&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
      The statistical analysis was performed using the Microsoft Excel 2016. Subjects were&#xD;
      categorized into two age groups: &lt;18 years (pediatric) and ≥18 years (adult). Total doses of&#xD;
      VD supplements were added to calculate cumulative supplementation and daily supplementation&#xD;
      was calculated by dividing cumulative dose by duration of supplementation.&#xD;
&#xD;
      Descriptive statistics median (interquartile range, IQR) were calculated for numerical data&#xD;
      while frequency (percentage) for categorical data. Frequencies of subjects with VD toxicity&#xD;
      were derived and their correlates were evaluated in the both the age groups. Demographics&#xD;
      (age and gender), calcium status of subjects, indications, formulation strengths, frequency,&#xD;
      duration, cumulative and daily dose of supplementation were generated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Potential vitamin D toxicity</measure>
    <time_frame>April 2020 to March 2021</time_frame>
    <description>Frequency of potential vitamin D Toxicity and use of VD supplementation including prescribed or self-medicated, indications for prescription, formulation strength, total dosage, frequency and duration will be determined.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">186</enrollment>
  <condition>Vitamin D Toxicity</condition>
  <arm_group>
    <arm_group_label>Pediatric Subjects and adults</arm_group_label>
    <description>Subjects were categorized into two age groups: &lt;18 years (pediatric) and ≥18 years (adult).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatrics and adults</arm_group_label>
    <description>Subjects were categorized into two age groups: &lt;18 years (pediatric) and ≥18 years (adult).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum 25OHD testing</intervention_name>
    <description>Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels &gt;150 ng/ml were contacted via telephone.</description>
    <arm_group_label>Pediatric Subjects and adults</arm_group_label>
    <arm_group_label>Pediatrics and adults</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects tested for serum 25OHD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects WITH serum 25OHD levels &gt;150 ng/ml.&#xD;
&#xD;
          -  Only the initial results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum 25OHD levels &lt;150ng/ml,&#xD;
&#xD;
          -  Incomplete clinical history&#xD;
&#xD;
          -  Whose contact numbers were unavailable&#xD;
&#xD;
          -  Who were not answering telephone calls&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>3500</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University Hospital, Pakistan</investigator_affiliation>
    <investigator_full_name>Siraj Muneer</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To maintain confidentiality all identifiers were removed, and study identity numbers were generated. Individual data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT05139576/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT05139576/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT05139576/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

